Related Experiment Video
Updated: Jun 18, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute
Hua Zhang1, Xue-Qun Luo, Peng Zhang
1Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory for Biocontrol, Sun Yat-Sen University, Guangzhou, PR China.
Background:
Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regulations in the progress of adult leukemia. The role of miRNAs in pediatric leukemia still needs to be established. The purpose of this study was to investigate the aberrantly expressed miRNAs in pediatric acute leukemia and demonstrate miRNA patterns that are pediatric-specific and prognostic parameter-associated.
Methodology/Principal Findings:
A total of 111 pediatric bone marrow samples, including 99 patients and 12 normal donors, were enrolled in this study. Of those samples, 36 patients and 7 normal samples were used as a test cohort for the evaluation of miRNA profiling; 63 pediatric patients and 5 normal donors were used as a validation cohort to confirm the miRNA differential expression. Pediatric ALL- and AML-specific microRNA expression patterns were identified in this study. The most highly expressed miRNAs in pediatric ALL were miR-34a, miR-128a, miR-128b, and miR-146a, while the highly expressed miRNAs in pediatric AML were miR-100, miR-125b, miR-335, miR-146a, and miR-99a, which are significantly different from those reported for adult CLL and AML. miR-125b and miR-126 may serve as favorable prognosticators for M3 and M2 patients, respectively. Importantly, we identified a "miRNA cascade" associated with central nervous system (CNS) relapse in ALL. Additionally, miRNA patterns associated with prednisone response, specific risk group, and relapse of ALL were also identified.
Conclusions/Significance:
There are existing pediatric-associated and prognostic parameter-associated miRNAs that are independent of cell lineage and could provide therapeutic direction for individual risk-adapted therapy for pediatric leukemia patients.
Insights
This study identifies specific microRNAs (miRNAs) in pediatric leukemia, revealing distinct patterns for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). These pediatric-specific miRNAs offer potential for targeted therapies and improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) are increasingly recognized for their role in adult malignancies, including leukemia.
- The specific involvement and patterns of miRNAs in pediatric leukemia remain less understood.
- Establishing these patterns is crucial for understanding disease mechanisms and developing targeted treatments.
Purpose of the Study:
- To investigate aberrantly expressed miRNAs in pediatric acute leukemia.
- To identify miRNA expression patterns specific to pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
- To determine if these miRNA patterns are associated with prognostic parameters and clinical outcomes.
Main Methods:
- Analysis of 111 pediatric bone marrow samples (99 patients, 12 controls).
- miRNA profiling using test and validation cohorts.
- Differential expression analysis to identify pediatric ALL- and AML-specific miRNAs.
Main Results:
- Identified distinct miRNA expression patterns for pediatric ALL and AML, differing from adult leukemia.
- Found specific miRNAs (e.g., miR-125b, miR-126) potentially associated with favorable prognoses in certain subtypes.
- Discovered a "miRNA cascade" linked to central nervous system relapse in ALL and patterns related to prednisone response and risk groups.
Conclusions:
- Pediatric leukemia exhibits unique miRNA profiles, independent of cell lineage.
- These pediatric-specific and prognostic parameter-associated miRNAs can guide individualized, risk-adapted therapeutic strategies.
- The findings pave the way for novel therapeutic directions in pediatric leukemia treatment.
